Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales.

J&J (JNJ) Beats on Q1 Earnings, Suspends COVID Jab Sales View

Johnson & Johnson (JNJ) stock is on the move Tuesday as investors react to the company's earnings report for the first quarter of 2022. The post Why Is Johnson & Johnson (JNJ) Stock in Focus Today?

Why Is Johnson & Johnson (JNJ) Stock in Focus Today?

Johnson & Johnson (NYSE:JNJ ) Q1 2022 Earnings Conference Call April 19, 2022 8:30 AM ET Company Participants Joe Wolk - Executive Vice President & Chief Financial Officer Jessica Moore - Vice President of Investor Relations Ashley McEvoy - Executive Vice President & Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President & Worldwide Chairman, Pharmaceuticals Thibaut Mongon - Executive Vice President & Worldwide Chairman, Consumer Health Conference Call Participants Larry Biegelsen - Wells Fargo Chris Schott - JPMorgan Joanne Wuensch - Citi Chris Shibutani - Goldman Sachs Louise Chen - Cantor Fitzgerald Josh Jennings - Cowen Terence Flynn - Morgan Stanley Matt Miksic - Credit Suisse Geoff Meacham - Bank of America Danielle Antalffy - SVB Leerink Operator Good morning, and welcome to Johnson & Johnson's First Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference.

Johnson & Johnson (JNJ) Management on Q1 2022 Results - Earnings Call Transcript

Johnson & Johnson (NYSE: JNJ) shares are trading higher Tuesday after the company reported mixed financial results and increased its dividend. Johnson & Johnson said first-quarter revenue grew 5% year-over-year to $23.43 billion, which came in below the $23.67 billion estimate.

What's Going On With Johnson & Johnson Stock?

Shares of Johnson & Johnson (NYSE: JNJ) are down 1.0% in premarket trading on Tuesday after the U.S. company reported weaker-than-expected Q1 revenue and lowered its guidance for the future. J&J Q1 financial highlights Net income printed at $5.15 billion that translates to $1.93 per share.

J&J Q1 results: there's positive narratives in all three of our segments

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.69% and 1.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (JNJ) Tops Q1 Earnings Estimates

The company also suspends guidance on sales of its Covid-19 vaccine, citing 'global supply surplus and demand uncertainty.'

Johnson & Johnson Beats Estimates, Cuts Guidance

Adobe

Atai Life Sciences BV

COMPASS Pathways

Cybin

Delta Air Lines

GW Pharmaceuticals

Home Depot

JPMorgan Chase & Co

Lowe's

Mind Medicine MindMed

Netflix

PayPal

Twitter

Wells Fargo

Walmart

Interested in Investing in Psychedelics? Check Out This Podcast.

Johnson & Johnson Beats Profit Estimates but Stock Dips on Guidance Cut

J&J is now forecasting 2022 sales of $94.8 billion to $95.8 billion, about $1 billion lower than the guidance provided in January.

J&J lowers 2022 revenue and earnings expectations, stops giving Covid vaccine sales guidance

Shares of Johnson & Johnson JNJ, -1.25% sank 3.2% in premarket trading Tuesday after the pharmaceutical and consumer products company topped first-quarter profit expectations but missed on revenue, and cut its full-year outlook, as the pharmaceuticals business disappointed. Net income fell to $5.15 billion, or $1.93 a share, from $6.20 billion, or $2.32 a share, in the year-ago period.

J&J stock sinks after revenue misses and full-year outlook was cut, as drug sales disappoint

(Reuters) -Johnson & Johnson on Tuesday suspended the sales forecast for its COVID-19 vaccine due to global supply surplus and demand uncertainty, sending its shares down 2.6% in premarket trading.

Johnson & Johnson suspends sales forecast for COVID-19 vaccine

Johnson & Johnson JNJ, -1.25% said Tuesday it is raising its quarterly dividend by 6.6%, to $1.13 a share from $1.06 a share. The new dividend will be payable June 7 to shareholders of record on May 24.

J&J boosts dividend to lift implied yield to above 2.5%

Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93 decreasing 16.8% and adjusted earnings per share of $2.67 increasing 3.1%* Company maintaining 2022 full-year guidance for adjusted operational earnings per share and base business operational sales Given global supply surplus and demand uncertainty, the Company is suspending COVID-19 Vaccine sales guidance, with no impact to adjusted operational earnings per share guidance NEW BRUNSWICK, N.J. , April 19, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022.

Johnson & Johnson Reports Q1 2022 Results

NEW BRUNSWICK, N.J. , April 19, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 6.6% increase in the quarterly dividend, from $1.06 per share to $1.13 per share.

Johnson & Johnson Announces Dividend Increase of 6.6%

Moderna

Novavax

Coronavirus vaccine stocks worth knowing as Covid-19 remains a global public health emergency.

Best Stocks To Invest In Now? 3 Coronavirus Vaccine Stocks To Know

Apple

Apple Inc (NASDAQ:AAPL) has been regarded as the most defensive stock in times of high volatility. Whereas the stock looked strong in the wake of global supply chain challenges, cracks are emerging from Covid-19 curbs in China.

Apple and JNJ are two defensive names. Which is better currently?

Intuitive Surgical

Stryker

Stryker, Johnson & Johnson, and Intuitive Surgical can be counted on to be steady performers in your portfolio.

The Safest Healthcare Stocks in the World

AbbVie

Abbott Labs

Merck

Pfizer

Investors who like to follow the movements of hedge funds might be interested in the drug companies that made the list of the top 25 holdings among hedge funds, as reported by Kiplinger.

Big Pharma Favorites of Hedge Funds

J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.

J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings

Kinder Morgan

Parker-Hannifin

Schlumberger

Travelers

After years of a low interest rate environment, many investors have turned to equities, not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.

5 Analyst Favorite Blue Chip Stocks Are Expected to Have Dividend Hikes This Week

Johnson & Johnson said on Monday it had agreed to pay $99 million to settle opioid-related claims by the state of West Virginia and its subdivisions.

J&J settles with West Virginia on opioid litigation for $99 million

Halliburton

Lockheed Martin

Before markets opened Wednesday, JPMorgan beat a modest revenue estimate and missed on profits.

Earnings Previews: Halliburton, Johnson & Johnson, Lockheed Martin, Truist

NextEra Energy

Philip Morris

Although bear markets can be scary, they're the perfect time to put your money to work.

News for Johnson & Johnson Stock (JNJ)